Glen Liszczak

Glen Liszczak

Auto-generated profile, based on publicly available information

Glen Liszczak

Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Science
Verified
Journal Article
Closed access
XZXiaoming Zhou
Xiaoming Zhou
LSLily Sumrow
Lily Sumrow
KTKyuto Tashiro
Kyuto Tashiro
LSLillian Sutherland
Lillian Sutherland
DLDaifei Liu
Daifei Liu
SMSteven L. McKnight
Steven L. McKnight
Protein domains of low sequence complexity do not fold into stable, three-dimensional structures. Nevertheless, proteins with these sequences assist in many aspects of cell organization, including assembly of nuclear and cytoplasmic structures not surrounded by membranes. The dynamic nature of these cellular assemblies is caused by the ability of low-complexity domains (LCDs) to transiently self-associate through labile, cross-β structures. Mechanistic studies useful for the study of LCD self-association have evolved over the past decade in the form of simple assays of phase separation. Here, we have used such assays to demonstrate that the interactions responsible for LCD self-association can be dictated by labile protein structures poised close to equilibrium between the folded and unfolded states. Furthermore, missense mutations causing Charcot-Marie-Tooth disease, frontotemporal dementia, and Alzheimer’s disease manifest their pathophysiology in vitro and in cultured cell systems by enhancing the stability of otherwise labile molecular structures formed upon LCD self-association.

14 June 2023 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
KTKyuto Tashiro
Kyuto Tashiro
SWSven Wijngaarden
Sven Wijngaarden
JMJugal Mohapatra
Jugal Mohapatra
JRJohannes G. M. Rack
Johannes G. M. Rack
IAIvan Ahel
Ivan Ahel
GLGlen Liszczak
Glen Liszczak

7 December 2021 in eLife
Verified
Journal Article
Open access
JMJugal Mohapatra
Jugal Mohapatra
KTKyuto Tashiro
Kyuto Tashiro
RBRyan L Beckner
Ryan L Beckner
JSJorge Sierra
Jorge Sierra
JKJessica A Kilgore
Jessica A Kilgore
GLGlen Liszczak
Glen Liszczak
Serine ADP-ribosylation (ADPr) is a DNA damage-induced post-translational modification catalyzed by the PARP1/2:HPF1 complex. As the list of PARP1/2:HPF1 substrates continues to expand, there is a need for technologies to prepare mono- and poly-ADP-ribosylated proteins for biochemical interrogation. Here, we investigate the unique peptide ADPr activities catalyzed by PARP1 in the absence and presence of HPF1. We then exploit these activities to develop a method that facilitates installation of ADP-ribose polymers onto peptides with precise control over chain length and modification site. Importantly, the enzymatically mono- and poly-ADP-ribosylated peptides are fully compatible with protein ligation technologies. This chemoenzymatic protein synthesis strategy was employed to assemble a series of full-length, ADP-ribosylated histones and show that ADPr at histone H2B serine 6 or histone H3 serine 10 converts nucleosomes into robust substrates for the chromatin remodeler ALC1. We found ALC1 preferentially remodels ‘activated’ substrates within heterogeneous mononucleosome populations and asymmetrically ADP-ribosylated dinucleosome substrates, and that nucleosome serine ADPr is sufficient to stimulate ALC1 activity in nuclear extracts. Our study identifies a biochemical function for nucleosome serine ADPr and describes a new, highly modular approach to explore the impact that site-specific serine mono- and poly-ADPr have on protein function.

6 February 2019 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
GLGlen P. Liszczak
Glen P. Liszczak
TMTom W. Muir
Tom W. Muir

21 March 2022 in ACS Chemical Biology
Verified
Journal Article
Closed access
KTKyuto Tashiro
Kyuto Tashiro
JMJugal Mohapatra
Jugal Mohapatra
CBChad A. Brautigam
Chad A. Brautigam
GLGlen Liszczak
Glen Liszczak

4 November 2025 in bioRxiv
Verified
Preprint
Open access
SBSara Charlotte Buch-Larsen
Sara Charlotte Buch-Larsen
IHIvo Alexander Hendriks
Ivo Alexander Hendriks
KTKyuto Tashiro
Kyuto Tashiro
JEJonas D. Elsborg
Jonas D. Elsborg
SVSergey Vakhrushev
Sergey Vakhrushev
MNMichael L. Nielsen
Michael L. Nielsen
ADP-ribosylation (ADPr) is a regulatory post-translational modification targeting nine amino acid residues. Glutamate- and aspartate-linked ADPr (Glu/Asp-ADPr) is chemically unstable during sample preparation for conventional mass spectrometry (MS)-based proteomics workflows, limiting its detection. Here, we systematically assessed the stability of ADPr linkages using synthetic peptides and confirmed that ester-linked Glu/Asp-ADPr is lost under alkaline conditions, elevated temperatures, or through hydrolysis by wildtype Af1521. We established an acidic enrichment workflow encompassing an Af1521 mutant, robustly preserving Glu/Asp-ADPr enabling their site-specific and systems-wide MS analysis. Applying this strategy to cytokine-stimulated A549 and HeLa cells, we identified >600 Glu/Asp-ADPr and >200 Cys-ADPr sites. Our analysis uncovered that Glu/Asp-ADPr marks distinct cytoplasmic protein networks enriched in immune functions, contrasting with Ser-ADPr typically observed on nuclear and chromatin-associated proteins. Quantitative profiling revealed reproducible ADPr patterns specific to cell type and treatment. Notably, PARP10 promoted Glu/Asp modification of ubiquitin, highlighting crosstalk between ADPr and ubiquitin signaling. Across interferon treatments, we identified a conserved network of antiviral PARPs and associated cofactors extensively modified on Glu/Asp residues, emphasizing residue-specific ADPr as a regulator of innate immune signaling. Together, our work establishes an MS-based proteomics workflow for identification of Glu/Asp-ADPr, provides a resource of site-specific modification events, and reveals residue-specific ADPr dynamics in immune signaling.